With experience of conducting clinical trials in South Africa, Kenya, Uganda, Tanzania, Rwanda, Botswana and Zambia, orphan reach is a CRO in South Africa that can fully leverage the benefits of this vast region, including:
• South Africa’s location in the Southern Hemisphere reduces the impact of seasonality and makes it a prime location for allergy and infectious disease studies.
• Rapid patient recruitment resulting from large populations in various therapeutic areas (many treatment naive), due to its unique socio-economic mix.
• Large pool of highly trained investigators, compliant with ICH-GCP principles, combined with stringent regulatory standards ensures study data from trials in Africa is a valuable component to FDA submissions.
• Africa offers a highly cost effective solution in comparison to the US and Western Europe.
The South African clinical team is highly experienced in conducting clinical trials across the whole of Africa and consists of pharmacists, nurses, lab and other science graduates and post-graduates in paramedical disciplines. Their therapeutic expertise includes Immunology, Anti-Infection, Respiratory and Oncology.
Realise the advantages of Africa with orphan reach.